BCL2L1 and ovarian carcinoma: In this case, apoptosis will require both the direct inactivation of these pathways by specific inhibitors leading to BIM accumulation and its desequestration from BCL-XL by a BH3-mimetic molecule, as observed in SKOV3 treated with the combination BEZ235/CI-1040/ABT-737.21 In both situations, it should be noticed that BH3-mimetic molecules are helpful to sensitize ovarian carcinoma cells to the induction of BIM mediated by the inhibition of EGFR cell signalling pathways.